Hot Features
プレミアム
Zentalis Pharmaceuticals Inc (ZNTL)
NASDAQ
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets a... Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. 詳細を表示
Azenosertib Fast Track Designation granted for Cyclin E1 positive patients by U.S. Food and Drug Administration (FDA) Manuscript focused on role of Cyclin E1/CDK2 activation predicting...
SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small...
SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small...
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small...
Julie Eastland appointed Chief Executive Officer, President and Director Ingmar Bruns, M.D., appointed Chief Medical Officer Scott Myers appointed to the Board of Directors as Chairperson SAN...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.602 | -20.6023271732 | 2.922 | 3.025 | 2.16 | 2189332 | 2.60123061 | CS |
| 4 | -0.6238 | -21.190298254 | 2.9438 | 3.33 | 2.16 | 1551892 | 2.85703276 | CS |
| 12 | -0.78 | -25.1612903226 | 3.1 | 4.44 | 2.16 | 1381678 | 3.18929726 | CS |
| 26 | -2.205 | -48.729281768 | 4.525 | 5.44 | 2.16 | 1515901 | 3.4321962 | CS |
| 52 | -10.85 | -82.38420653 | 13.17 | 18.07 | 2.16 | 1315362 | 5.86194734 | CS |
| 156 | -63.33 | -96.4661081493 | 65.65 | 65.68 | 2.16 | 918409 | 15.11215382 | CS |
| 260 | -22.37 | -90.6034831916 | 24.69 | 87.19 | 2.16 | 671132 | 20.5890851 | CS |
Awl416
4月前
glenn1919
4月前
Monksdream
5月前
ANTADOG
5年前
ANTADOG
5年前
ANTADOG
5年前
ANTADOG
5年前
ANTADOG
5年前
ANTADOG
5年前
ANTADOG
5年前
ANTADOG
5年前
ANTADOG
5年前
crudeoil24
5年前
crudeoil24
5年前
crudeoil24
5年前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
